Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
Fortune Minerals Reports Successful NICO Project Bismuth Test Work Results for the Planned Alberta Refinery